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The extracellular region of the transmembrane neural cell adhesion molecule (NCAM-EC) is shed as a soluble fragment at elevated levels
in the schizophrenic brain. A novel transgenic mouse line was generated to identify consequences on cortical development and function
of expressing soluble NCAM-EC from the neuron-specific enolase promoter in the developing and mature neocortex and hippocampus.
NCAM-EC transgenic mice exhibited a striking reduction in synaptic puncta of GABAergic interneurons in the cingulate, frontal associ-
ation cortex, and amygdala but not hippocampus, as shown by decreased immunolabeling of glutamic acid decarboxylase-65 (GAD65),
GAD67, and GABA transporter 1. Interneuron cell density was unaltered in the transgenic mice. Affected subpopulations of interneurons
included basket interneurons evident in NCAM-EC transgenic mice intercrossed with a reporter line expressing green fluorescent protein
and by parvalbumin staining. In addition, there appeared to be a reduction in excitatory synapses, as revealed by synaptophysin staining
and apical dendritic spine density of cortical pyramidal cells. Behavioral analyses demonstrated higher basal locomotor activity of
NCAM-EC mice and enhanced responses to amphetamine and ()-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine
maleate compared with wild-type controls. Transgenic mice were deficient in prepulse inhibition, which was restored by clozapine but
not by haloperidol. Additionally, NCAM-EC mice were impaired in contextual and cued fear conditioning. These results suggested that
elevated shedding of NCAM perturbs synaptic connectivity of GABAergic interneurons and produces abnormal behaviors that may be
relevant to schizophrenia and other neuropsychiatric disorders.
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Introduction
The neural cell adhesion molecule (NCAM) controls diverse as-
pects of axon and dendritic development, synaptogenesis, and
plasticity. Intercellular adhesive events are regulated through ho-
mophilic and heterophilic binding interactions mediated by the
NCAM extracellular region (NCAM-EC), which consists of five
immunoglobulin-like and two fibronectin III domains (Panicker
et al., 2003). Alternative splicing of the NCAM gene generates
three principal variants that differ only in the cytoplasmic do-
main: 180 and 140 kDa transmembrane isoforms found in neu-
rons and other cells and a 120 kDa glycophosphatidyl inositol-
linked form present mostly in glia. NCAM140 is preferentially
expressed in developing neurons and regulates hippocampal-
based learning and migration of olfactory granule cell precursors
(Stork et al., 2000). In contrast, NCAM180 is restricted primarily
to postsynaptic densities of mature neurons, where it is involved
in synaptic functions (Persohn and Schachner, 1990; Dityatev et
al., 2000), including those regulating sensory gating (Wood et al.,
1998) and fear conditioning (Stork et al., 2000). The extracellular
region of all NCAM isoforms is subject to posttranslational poly-
sialylation, which modulates cell migration, axon growth, and
activity-dependent synaptic plasticity (Muller et al., 1996; Rut-
ishauser and Landmesser, 1996). NCAM knock-out (KO) mice
display deficits in learning, memory, hippocampal long-term po-
tentiation (LTP) (Cremer et al., 1994; Bukalo et al., 2004), im-
paired migration of olfactory neurons (Cremer et al., 2000), de-
creased sensory gating (Wood et al., 1998), and increased anxiety,
aggression, and hyperactivity (Stork et al., 1999, 2000).
Recent evidence has revealed a dysregulation of NCAM asso-
ciated with schizophrenia (Vawter, 2000). A soluble NCAM frag-
ment consisting of most of its extracellular region is present at
elevated levels in postmortem brain and in CSF (Poltorak et al.,
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1995; Honer et al., 1997; van Kammen et al., 1998; Vawter et al.,
1998a,b, 2001), correlating with the severity and duration of
schizophrenia (Vawter et al., 1998b). Soluble NCAM-EC in the
schizophrenic brain does not arise from overexpression of a mi-
nor secreted splice variant of the NCAM extracellular region
(Vawter et al., 2000) but appears to be derived from proteolytic
cleavage (shedding) of transmembrane NCAM isoforms (Vawter
et al., 2001). Soluble NCAM has been widely documented in the
normal brain as well as neuronal cell cultures (Walmod et al.,
2004), but the protease responsible for NCAM cleavage has not
been identified. Soluble NCAM has the potential to act as a
dominant-negative inhibitor of intact NCAM interactions, and
regulation of shedding could be important in the mechanism of
neuronal process outgrowth and synaptogenesis.
To study the effect of overproduction of soluble NCAM-EC in
the brain, we generated transgenic mice that express the
NCAM-EC fragment from the neuron-specific enolase (NSE)
promoter. This promoter is induced late in neuronal differentia-
tion and attains maximal activation in adults (Forss-Petter et al.,
1990). This strategy circumvented the early embryonic lethality
of mice expressing secreted NCAM generated by a genetic
knock-in approach (Rabinowitz et al., 1996). These mice may
reflect the brain expression of NCAM in schizophrenia, in which
transmembrane and soluble forms of NCAM are present, and the
level of the NCAM-EC fragment is 50% that of NCAM180 and
NCAM140 (Vawter et al., 1998a). NCAM-EC transgenic mice
exhibited a striking decrease in synaptic terminals of subpopula-
tions of GABAergic interneurons in frontal cortical areas and the
amygdala. The mice also displayed abnormal behaviors that in-
cluded deficits in sensory gating and emotional memory as well as
alterations in motor performance. These results suggested that
abnormal expression of secreted NCAM may perturb frontal cor-
tical and amygdala circuitry by interfering with presynaptic func-
tion of GABAergic interneurons and possibly other excitatory
neurons associated with rodent models of schizophrenia.
Materials and Methods
Construction of plasmids. The pNSE-NCAM plasmid was constructed
using the pUC19-based pMG2 expression plasmid (B. Popko, University
of Chicago, Chicago, IL). A hemagglutinin (HA) tag and BamH1 site
were added by PCR to the 3-end of the cDNA sequence of the rat NCAM
extracellular region (lacking the variable alternative splice exon). This
resulted in a 2.2 kb HindIII–BamH1 fragment that represented the entire
open-reading frame of the NCAM extracellular cDNA sequence and HA
tag. The 1.8 kb NSE promoter was removed from pNSElacZ (G. Sutcliffe,
The Scripps Research Institute, La Jolla, CA) and subcloned 5 to the 2.2
kb NCAM-HA fragment into pMG2. -Globulin splice sites and poly(A)
signal sequences from the pMG2 vector were retained 3 to the
NCAM-HA coding region. Digestion with NotI released a 5.7 kb linear
construct free of plasmid DNA for transgene injection.
Transgenic mice and genotyping. Transgenic mice expressing the
pNSE-NCAM cDNA (NCAM-EC) were generated at the University of
North Carolina Chapel Hill Transgenic Facility. The linearized 5.7 kb
pNSE-NCAM construct was microinjected into fertilized C57BL/6 ova.
Eggs were transferred to the oviducts of pseudopregnant females of the
same strain. Injection of 100 eggs resulted in the birth of 42 pups.
Genomic DNA was extracted from tail biopsies from 11 transgenic mice
and characterized for transgene insertion by PCR and Southern blotting.
Specific PCR primers (NCAM 1964, GCAGTGACCACGTCATGCTC;
EXON3R, GGTGAATTCTTTGCCAAAGTGA) were designed for the
transgenic construct so that endogenous NCAM DNA was not amplified.
For Southern blotting, DNA was digested with EcoRI and probed with a
1.1 kb fragment hybridizing to the HA and -globulin sequences. Behav-
ioral studies were conducted with wild-type (WT) and NCAM-EC trans-
genic mice when they were 4 – 6 months of age; approximately equal
numbers of males and females were tested from each genotype with 7–10
mice/genotype/experiment/condition. Founder males (3237, 3250, and
3272) were used to establish separate transgenic lines and were back-
crossed to C57BL/6 for five to eight generations. Line 3237 was used for
behavioral studies.
Transgenic C57BL/6 harboring a bacterial artificial chromosome
(BAC) construct expressing enhanced green fluorescent protein
(EGFP)-WT in a subpopulation of basket interneurons driven by the
glutamic acid decarboxylase-67 (GAD67) promoter were generated as
described previously (Chattopadhyaya et al., 2004). These mice were
intercrossed with NCAM-EC transgenic mice (EGFP-NCAM) for five
generations for analysis of the effect of the transgene on basket
interneurons.
Western blot analysis and Nissl staining. Extracts were prepared from
cerebral hemispheres of adult NCAM-EC transgenic mice and WT litter-
mates in radioimmunoprecipitation assay lysis buffer, clarified by cen-
trifugation, and electrophoresed (100 g of protein) on 7.5% SDS-
polyacrylamide gels. Proteins were transferred to nitrocellulose filters,
which were blocked with 2% bovine serum albumin and incubated with
monoclonal anti-HA antibodies (1:1000) (BabCo, Richmond, CA) or
monoclonal anti-OB11 antibody (1:500) against the NCAM cytoplasmic
domain (Sigma, St. Louis, MO) for 2 h. Antibody binding was detected
by enhanced chemiluminescence.
For fractionation, brains were homogenized in 5 ml of ice-cold PBS
with 0.1 mg/ml phenylmethylsulfonyl fluoride, 2 mg/ml pepstatin A, 2
mg/ml aprotinin, and 2 mg/ml leupeptin. Homogenates were centri-
fuged at 42,000  g for 30 min at 4°C, and supernatants were collected to
yield the soluble fraction. For Nissl staining, NCAM-EC transgenic mice
and WT littermates were anesthetized and perfused, and brains were
postfixed and processed for Nissl staining as described previously (De-
myanenko et al., 1999).
Immunofluorescence and cell-density analysis. Adult transgenic and WT
littermate control mice were processed for cryostat sectioning, and brains
were sectioned coronally (12 m) (Demyanenko et al., 1999). For im-
munofluorescence staining, sections were treated with 1% NP-40/PBS
and blocked in 5% milk/5% normal goat or donkey serum. Sections were
washed in PBS and incubated for 1 h in 1% serum containing one the
following primary antibodies: 5 g/ml mouse anti-GAD65 (Develop-
mental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), 2– 4
g/ml rabbit anti-GAD67 (AB108; Chemicon, Temecula, CA), 6 g/ml
mouse anti-parvalbumin (P-3171; Sigma), mouse anti-calretinin
[monoclonal antibody (MAB) 1568; Chemicon] at a dilution of 1:2000,
1.6 g/ml rabbit anti-GABA transporter 1 (GAT-1), 5 g/ml rabbit anti-
NCAM polyclonal antibody (AB5032; Chemicon), or 3 g/ml mouse
anti-synaptophysin (MAB 5258; Chemicon). Sections were washed in
1% NP-40/PBS and incubated for 30 min in 1% serum containing FITC-
conjugated secondary antibodies, 1:500 for Alexa 488 (Molecular Probes,
Eugene, OR) or 1:150 for tetramethylrhodamine isothiocyanate
(TRITC)-conjugated goat anti-rabbit IgG and TRITC-conjugated goat
anti mouse IgG (Jackson ImmunoResearch, West Grove, PA). Sections
were rinsed, mounted in Vectashield (Vector Laboratories, Burlingame,
CA), and imaged by confocal microscopy (Olympus FV500; Olympus,
Tokyo, Japan) with a 60 objective at the University of North Carolina
Microscopy Facility (Dr. Robert Bagnell, Director, Department of Pa-
thology, University of North Carolina School of Medicine). For EGFP-
transgenic mice, brains were sectioned at 100 m and analyzed directly.
Images were acquired using laser excitation (488 nm), laser power (10%),
and aperture size (102 m) and analyzed using Scion (Frederick, MD)
Image software. For each image, the perisomatic signals (puncta rings) or
neuropil area from at least six randomly selected target neurons were
delineated and then pixel density within the delineated area was calcu-
lated and averaged as described previously (Huang et al., 1999). Four or
more sections from each of three to seven mice of each genotype were
analyzed. A total of at least 200 cells were analyzed for each genotype.
NIH Image J software was used for analysis of total neuropil area (4
mice/genotype; 16 images per genotype). Data from at least 20 images
from each genotype were averaged to derive the pixel density of puncta
ring and/or neuropil.
Interneuron cell numbers within layer II/III were counted blind after
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immunostaining by epifluorescence microscopy in serial coronal sec-
tions matched for rostrocaudal level by bregma distance throughout the
cingulate cortex in WT and NCAM-EC transgenic littermates. Sections
were stained for either parvalbumin or calretinin and examined by indi-
rect immunofluorescence or scored directly from brain sections of
EGFP-expressing mice. The total cell number was then divided by the
area of the image (7000 m 2) to obtain cell density. The density was
reported as cells per square millimeter. In all cases, three to five mice of
each genotype (two to six sections per mouse) were analyzed, and 150 –
200 cells per genotype were scored.
Analysis of spine densities on apical dendrites of pyramidal neurons.
NCAM-EC mice were intercrossed with Thy1/yellow fluorescent protein
(YFP) line H mice (Feng et al., 2000), in which layer V pyramidal cells are
fully labeled with enhanced YFP. Apical dendritic branches located in
layer II/III of the cingulate cortex were imaged by confocal microscopy,
and Z-stacked projections were used for measurement of spine density.
At least 30 dendritic segments from 16 sections were measured from
wild-type and mutant mice (two mice of each genotype). The number
and density of the spines were measured using the Neurolucida software
as described previously for the Thy1/YFP line H mice (Demyanenko et
al., 2004).
General neurophysiological status. The neurophysiological screen con-
sisted of tests that involved an initial evaluation as well as assessments of
orienting and reflexive behavior, postural and righting reflexes, paw
strength, coordination and balance, and anxiety-like behavior (Ribar et
al., 2000; Pogorelov et al., 2005). All measures, except where noted, were
scored on a multipoint system. Normal responses were scored as 0, neg-
ative responses (1 to 6) denoted deficiencies, and positive scores (1
to  6) reflected more proficient or exaggerated responses relative to
normal or 0 scores. In the initial evaluation, animals were examined for
evidence of changes in skin color, body tone, lacrimation or palperbral
closure, exophthalmus, convulsions or tremor, heart or respiration rates,
tail elevation or body posture, and barbering or hair loss. Assessments of
orientation and reflexive behavior included visual orientation to an ob-
ject (ability to orient to a dental mirror and follow its movement through
the visual field), visual placement (propensity of the mouse to extend its
forepaws just before contact with a flat surface), and whisker, eye, and ear
reflexes (orientation to whisker touch, eye blink in response to touch, and
ear twitch in response to touch with a dowel). Analyses of postural and
righting reflexes involved testing the ability of the mouse to maintain its
balance when its cage was shaken in a vertical or horizontal plane and for
the animal to right itself when placed on its back. Paw strength, coordi-
nation, and balance were examined by several tests. Evaluation of fore-
paw and rearpaw strength was determined by the ability of the mouse to
grasp a rod with its forepaws or rearpaws and its tenacity to hold the rod
when it was pulled away. The wire-hang task examined forepaw strength
and coordination by testing the ability of the mouse to remain suspended
on a vertical wire by its forepaws for 90 s. Coordination, balance, and
motor strength were studied by observing the time it took the mouse to
climb down and up a vertical pole and to traverse a horizontal pole. Mice
were also held by their tails for 60 s to ascertain whether they would
display abnormal crossing of hindlimbs or body contortion. Finally,
anxiety-like behaviors were evaluated in a zero maze for 5 min (Pogore-
lov et al., 2005). Behavior was videotaped with the investigator hidden
from the view of the mouse. Percentage of time in the open arms of the
maze was subsequently scored by an investigator who was unfamiliar
with the genotypes of the mice.
Open-field activity. Spontaneous activity was evaluated in an auto-
mated Omnitech Digiscan apparatus (AccuScan Instruments, Colum-
bus, OH) as described previously (Gainetdinov et al., 1999). WT and
NCAM-EC transgenic mice were placed into the open field, and activity
was summated at 5 min intervals over a 1 h period. Locomotion was
measured as the total distance covered in centimeters (horizontal activ-
ity), rearing was evaluated as the total number of vertical beam breaks
(vertical activity), and stereotypy was quantitated in terms of repetitive
breaks of a given beam with intervals of 1 s. Pharmacological responses
were also assessed after 60 min in the open field for baseline activity
followed immediately by treatment with vehicle (water), amphetamine
(2 or 4 mg/kg), or ()-5-methyl-10,11-dihydro-5H-dibenzo [a,d]
cyclohepten-5,10-imine maleate (MK-801) (0.2, 0.3, or 0.4 mg/kg, i.p.).
Prepulse inhibition of acoustic startle. Prepulse inhibition (PPI) of
acoustic startle was measured in a Med Associates (St. Albans, VT) ap-
paratus in the presence of a 64 dB white-noise background. Mice were
given three different types of trials. One trial type consisted of a 40 ms 120
dB white-noise startle stimulus. In a second, the startle stimulus was
preceded by a 20 ms prepulse stimulus that was 4, 8, or 12 dB above the
white-noise background. In a third trial type, no auditory stimulus was
presented, and these null trials served as control for background move-
ments by the animal. During testing, mice were acclimated to the appa-
ratus for 5 min and then given 74 test trials. In 30 of the trials, the 120 dB
stimulus was given alone (startle-only trials), whereas eight additional
trials served as null trials. For the remaining 36 trials, the prepulse stim-
ulus preceded the startle stimulus by 100 ms. Testing began with 10
startle-only trials, followed by combinations of the 36 prepulse trials, 10
startle-only trials and the eight null trials in a pseudorandom order;
testing was completed with 10 startle-only trials. The behavioral re-
sponses were measured as the peak startle response for each trial between
35 and 65 ms after the onset of the startle stimulus. Responses that fell
outside of this range or that were at a magnitude below that of null trials
were discarded. Inhibition of the startle response was calculated for each
intensity of prepulse as the ratio of prepulse trials to startle-only trials
subtracted from 1 and expressed as a percentage inhibition of response,
where %PPI  [1  (prepulse trials/startle-only trials)]*100. For phar-
macological studies, NCAM-EC mice and WT littermates were injected
30 min before PPI testing with vehicle (saline), haloperidol (0.05 or 0.2
mg/kg), or clozapine (1 or 3 mg/kg, i.p.).
Fear conditioning. Fear conditioning was conducted in a mouse fear-
conditioning apparatus (Med Associates). During the 3 min training
session, WT littermates and NCAM-EC transgenic mice were placed into
the apparatus, and after 2 min, a 72 dB tone was sounded for 30 s. Two
seconds before offset of the tone, a 0.4 mA scrambled foot-shock was
given, and the tone and shock terminated simultaneously. The mouse
remained in the chamber for an additional 30 s and then was returned to
its home cage. Twenty-four hours later, the animal was tested under one
of two conditions. For context testing, the mouse was returned to the
same chamber in which it was trained, and freezing behavior was scored
every 5 s over a 5 min period; no tone or shock was presented. Under cued
testing, the animal was placed into a chamber with a different floor that
appeared visually distinct from that used during training. After 2 min, the
72 dB tone was given for 3 min, but no shock was presented. All behaviors
were videotaped during the training and test sessions. Freezing behaviors
were scored subsequently over the 4 min period for training and the 5
min period for both test conditions by an observer who had no previous
knowledge of the genotypes of the mice.
Statistics. Image analyses of puncta rings and/or neuropil and evalua-
tion of interneuron cell density (cells per square millimeter) were statis-
tically calculated for each genotype using Student’s t test. Behavioral
analyses were conducted with the SPSS-11 programs of statistical tests
(SPSS, Chicago, IL), and all results are presented as means and SEM.
Responses on the neurophysiological screen were analyzed by t tests.
Spontaneous horizontal, vertical, and stereotypy activities were collapsed
and analyzed over the first hour by t tests for the two genotypes. For
amphetamine and MK-801 responses, the data were analyzed by univar-
iate ANOVA for the main effects of genotype and drug treatment. De-
composition analyses of main effects and significant interaction terms
were preformed using pairwise comparisons with Bonferroni correc-
tions. For PPI, baseline startle responses to the 120 dB tone were analyzed
by t tests for vehicle-treated WT and NCAM-EC mice. A univariate
ANOVA examined startle responses within each genotype for the various
drugs and their doses. PPI responses were evaluated with a repeated-
measures ANOVA (RMANOVA), and decomposition analyses were
used to determine differences in drug responses. The fear conditioning
data were analyzed by RMANOVA with decomposition analyses to ex-
amine effects at specific times. In all cases, p  0.05 was considered
significant.
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Results
Generation of NCAM-EC transgenic mice
To investigate potential neurological deficits of NCAM-EC over-
expression, we generated transgenic mice secreting soluble
NCAM-EC in the adult brain. A plasmid was generated (supple-
mental Fig. S1A, available at www.jneurosci.org as supplemental
material) in which expression of the entire NCAM-EC, including
its five Ig-like and two fibronectin III domains with a C-terminal
HA epitope tag, was placed under control of the NSE promoter.
This promoter is activated at low levels in all neurons during
terminal differentiation and reaches maximal levels in adult neu-
rons (Forss-Petter et al., 1990). The transgene was detected in
genomic DNA isolated from 11 of 42 transgenic mice by PCR and
Southern blotting (supplemental Fig. S1A, representative exam-
ples, available at www.jneurosci.org as supplemental material).
The copy number in different transgenic lines was estimated be-
tween 1 (3255) and 20 (3272) copies by comparison to known
amounts of NCAM-EC plasmid. The 11 transgenic mice were
bred to WT C57BL/6 mice, and all crosses showed germ-line
transmission. Expected litter sizes with equal numbers of males
and females indicated that there was no deleterious effect on the
viability of embryos. The transgenic mice were long lived and had
normal breeding capability.
Western blotting with HA antibodies was used to evaluate the
levels of expression of transgenic NCAM-EC protein in brain
extracts isolated from F1 offspring. Different levels of HA-tagged
NCAM-EC protein were expressed in transgenic lines (supple-
mental Fig. S1B, selected cases, available at www.jneurosci.org as
supplemental material). Epitope-tagged NCAM-EC had an ex-
pected molecular size of 110 kDa and appeared as a diffuse
band probably resulting from known carbohydrate modification
of NCAM. The soluble fraction isolated from brains of
NCAM-EC transgenic mice contained the majority of the HA-
tagged NCAM-EC protein (75% of total NCAM-EC in the
brain) estimated by immunoblotting (supplemental Fig. S1B,
available at www.jneurosci.org as supplemental material). West-
ern blotting of brain extracts with NCAM antibody OB-11, which
recognizes a common determinant in the intracellular domain of
both NCAM180 and NCAM140, showed that transgene expres-
sion of NCAM-EC did not alter the levels of endogenous NCAM
isoforms in the brain of most transgenic lines (supplemental Fig.
S1C, available at www.jneurosci.org as supplemental material).
Levels of NCAM-EC expression did not correlate with endoge-
nous NCAM expression across lines. Three founder males (3237,
3250, and 3272) expressing elevated levels of NCAM-EC protein
were chosen for establishing separate transgenic lines. These mice
were backcrossed to C57BL/6 for five to eight generations for
neuroanatomical and behavioral analyses. No differences in
GABAergic marker expression were observed among the three
lines analyzed. Line 3237 was chosen for behavioral analysis.
Expression and localization of NCAM-EC in brain
Nissl staining of adult brain sections showed no differences in the
size of the olfactory bulb, hippocampus, cerebellum, thalamus,
amygdala, or superior colliculus in NCAM-EC mice compared
with WT littermates (Fig. 1A,B). Unlike NCAM180 KO mice
(Wood et al., 1998), brain ventricles were not enlarged in
NCAM-EC mice. The cerebral cortex had a normal thickness
with all layers in the correct order. Golgi staining revealed typical
cortical neurons, including pyramidal cells with normal mor-
phology and dendritic orientation (data not shown). The expres-
sion and localization of the transgenic NCAM-EC fragment in
the adult brain was analyzed by immunoperoxidase staining with
HA antibodies. NCAM-EC was present in all layers of the trans-
genic neocortex where it was evident both in the neuropil and
soma of subsets of neurons in layers II-VI, as shown in the cin-
gulate cortex (Fig. 1C,E). A similar pattern of immunoreactivity
was observed in the motor, somatosensory, and visual cortices.
NCAM-EC was prominent in neuropil-rich areas of the hip-
pocampus (CA1, CA2, and CA3) and dentate gyrus (Fig. 1F,H).
NCAM-EC was also evident in the amygdala (Fig. 1 I) and cere-
bellum (Fig. 1K). Nonspecific immunoreactivity with HA anti-
bodies was not observed in the corresponding regions of WT
brain (Fig. 1D,G,J). Because a large fraction of NCAM-EC was
soluble, it was not possible to determine which cell types express
the transgene and which cells are binding targets of NCAM-EC.
Also, because antibodies against endogenous NCAM also recog-
nize NCAM-EC, potential region-specific alteration in endoge-
nous NCAM isoforms could not be evaluated.
Decreased GAD65, GAD67, and GAT-1 in GABAergic
interneurons of NCAM-EC transgenic mice
Glutamic acid decarboxylase is the rate-limiting enzyme leading
to the biosynthesis of GABA. GAD65 and GAD67, the major
isoenzymes of GAD in brain, are distinct gene products with
molecular weights of 65 and 67 kDa, respectively. GAD65 is en-
riched in nerve terminals of GABAergic inhibitory neurons,
where it may be activated during high-GABA demand, whereas
GAD67 is localized throughout the neuronal processes and soma,
where it may maintain basal GABA levels (Feldblum et al., 1993;
Esclapez et al., 1994). Because expression and/or activity of pre-
synaptic markers of GABAergic interneurons are decreased in the
prefrontal cortex in schizophrenia (Akbarian et al., 1995;
Ohnuma et al., 1999; Volk et al., 2000, 2001; Blum and Mann,
2002; Hashimoto et al., 2003), the expression of GAD65 and
GAD67 was analyzed in frontal cortical areas (cingulate and fron-
tal association cortex) of the NCAM-EC cerebral cortex by im-
munofluorescence staining. In the cingulate and frontal associa-
tion cortex of WT mice, prominent GAD65 immunofluorescence
was concentrated in discrete puncta rings, which represented
axon terminals and presynaptic boutons of GABAergic interneu-
rons, surrounding nonimmunoreactive soma of postsynaptic
neurons in cortical layers II-VI (Fig. 2, arrows). GAD65 immu-
nofluorescent staining in WT frontal areas was generally weaker
in neuropil but clearly above background (Fig. 2, inset; compare
nonimmune IgG). At equivalent rostrocaudal levels in the
NCAM-EC cingulate and frontal association cortex, GAD65 lo-
calization in puncta rings was significantly decreased to less than
half that of WT (puncta rings in NCAM-EC cingulate and frontal
association cortex was reduced by 62 and 59%, respectively) (Fig.
2). Punctate staining for GAD65 in the neuropil also was reduced
in transgenic frontal cortical areas but reached significance only
in the frontal association cortex (reduced by 62%). There was no
decrease in GAD65 fluorescent puncta rings surrounding pyra-
midal cell soma in the hippocampus (CA1 or CA2) (data not
shown).
GAD67 immunofluorescence in the cingulate cortex of WT
mice was present as puncta rings and as punctate staining in the
neuropil (Fig. 2). In the NCAM-EC cingulate cortex, GAD67-
labeled puncta rings showed a small but significant decrease of
16% compared with WT, whereas staining in the neuropil was
not affected. GABA transporter GAT-1 is enriched in presynaptic
nerve terminals of GABAergic interneurons in the cerebral cortex
(Minelli et al., 1995). WT mice showed prominent GAT-1 local-
ization in puncta rings surrounding immunonegative cell bodies
as well as in the neuropil of cingulate cortex (Fig. 2). In contrast,
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punctate staining for GAT-1 in the NCAM-EC cingulate cortex
was significantly decreased in puncta rings (24% reduction) and
neuropil (21% reduction) (Fig. 2).
Decreased synaptic puncta of interneurons in
NCAM-EC brain
Although immunofluorescence staining for GAD and GAT-1 was
decreased in the transgenic cortex, an appreciable amount of
labeling remained, suggesting that subpopulations of interneu-
rons were specifically affected. Cortical GABAergic interneuron
subpopulations display distinct electro-
physiological characteristics and expres-
sion patterns of calcium-binding proteins
such as parvalbumin. The parvalbumin-
expressing subpopulation accounts for
40 –50% of GABAergic interneurons in
the rodent neocortex (Kubota et al., 1994).
Parvalbumin interneurons include bas-
ket (wide arbor) and chandelier neurons
(Conde et al., 1994).
The effect of NCAM-EC overexpres-
sion on basket interneurons was examined
in NCAM-EC mice that were intercrossed
with a BAC transgenic mouse line (EGFP-
WT) expressing EGFP from the GAD67
promoter in subpopulations of basket in-
terneurons (Chattopadhyaya et al., 2004).
EGFP-fluorescent puncta rings surround-
ing cell soma were prominent in the cin-
gulate cortex of EGFP-WT mice (Fig. 3A).
NCAM-EC littermates (EGFP-NCAM)
showed a significant decrease of 24% in
fluorescent puncta rings compared with
WT mice (Fig. 3A,B). Fluorescent puncta
within the neuropil of EGFP-NCAM mice
were not significantly decreased, consis-
tent with the possibility that synaptic ter-
minals were selectively disrupted. A signif-
icant decrease of 23% in fluorescent
puncta rings was also observed in the
amygdala of EGFP-NCAM mice (Fig.
3A,B). There was no significant reduction
in EGFP-labeled puncta in the hippocam-
pus (Fig. 3A,B). Endogenous NCAM was
demonstrated to be localized in periso-
matic synaptic puncta of basket interneu-
rons within the cingulate cortex and
amygdala, shown by immunostaining for
NCAM in cortical sections from the
EGFP-WT mice (Fig. 3C). NCAM immu-
nostaining could be seen colocalized with
EGFP-labeled synaptic puncta surround-
ing the cell soma, as well as in the neuropil.
The decrease in immunofluorescence
of GABAergic neuronal markers in synap-
tic puncta rings in the NCAM-EC frontal
cortex may be a result of fewer presynaptic
GABAergic terminals or overall loss of
neuropil. To examine this distinction fur-
ther, the area occupied by neuropil ex-
cluding soma was measured in confocal
images of EGFP-WT and EGFP-NCAM
cortex matched for rostrocaudal level. The
average total area occupied by neuropil for EGFP-WT mice
(6601  26 m 2 per image) was not significantly different from
EGFP-NCAM mice (6533  212 m 2). These results were con-
sistent with a decrease in the number of synaptic terminals rather
than an overall loss of neuropil. In accord with this, fluorescent
puncta rings of neurons immunostained for parvalbumin in the
cingulate cortex were reduced by 90% in NCAM-EC compared
with WT mice (Fig. 3D). Because 80% of cortical parvalbumin-
positive neurons are GABAergic (Powell et al., 2003), it is reason-
able to conclude that synaptic terminals of parvalbumin-
Figure 1. Nissl staining of NCAM-EC transgenic brain and immunocytochemical localization of NCAM-EC protein. A, B, Nissl
staining of adult WT and NCAM-EC brain in a coronal section through the hippocampus (HC), thalamus (th), corpus callosum (cc),
lateral ventricle (LV), and dorsal third ventricle (D3V). Scale bar, 500 m. Immunoperoxidase staining with anti-HA antibodies in
adult transgenic cingulate cortex (C) shows localization in layers I-VI and no staining in WT cortex (D). Scale bar, 100 m. E,
NCAM-EC immunoreactivity in the cingulate of transgenic mice is evident in the neuropil and soma of large pyramidal-like neurons
(arrowhead) and nonpyramidal-like cells (arrow). Scale bar, 50 m. F, NCAM-EC staining in the hippocampus of transgenic mice
in CA1, CA2, and CA3 and the dentate gyrus (DG). G, No staining in WT hippocampus. Scale bar, 100 m. H, NCAM-EC staining in
the hippocampus and dentate gyrus is evident in the neuropil and cell bodies. Scale bar, 150 m. I, NCAM-EC staining in the
basolateral nucleus of amygdala of transgenic mice. J, No staining in WT amygdala. Scale bar, 100 m. K, NCAM-EC staining in the
cerebellum of transgenic mice. Scale bar, 100 m. IGL, Internal granular layer; Mo, molecular layer.
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expressing GABAergic interneurons are
decreased in NCAM-EC transgenic mice.
Interestingly, there was a significant re-
duction in immunofluorescence staining
for synaptophysin in the NCAM-EC cin-
gulate cortex. Approximately 40% reduc-
tion was observed both in puncta rings
(pixel density: WT, 135  6; NCAM, 81 
8; p  0.05) and in neuropil (pixel density:
WT, 159  10; NCAM, 98  9; p  0.05)
(Fig. 4A). Synaptophysin staining should
be fairly proportional to synapse density.
Because there are more excitatory syn-
apses in the cortex than inhibitory
synapses (DeFelipe et al., 2002), the sub-
stantial reduction of synaptophysin im-
munoreactivity in the transgenic cingulate
cortex suggested that synapses other than
those derived from GABAergic interneu-
rons were also disrupted. To determine
whether excitatory synapses were also
decreased in the NCAM-EC brain,
NCAM-EC transgenic mice were inter-
crossed with reporter mice (Thy1/YFP line
H) that express YFP from Thy-1 promoter
in layer V pyramidal neurons throughout
the cell soma, axons, dendrites, and den-
dritic spines (Feng et al., 2000; Demy-
anenko et al., 2004). Spine density on
branches of apical dendrites found in layer
II/III of the cingulate cortex in NCAM-
EC/Thy1 mice (1.7  0.2 spines/m) was
reduced by 40% when compared with
wild-type Thy1 mice (2.8  0.3 spines/
m) (Fig. 4B). Thus, excitatory synapses
also appeared to be reduced in the trans-
genic cortex.
Because a decrease in synaptic connec-
tivity might lead to loss of activity-
dependent cell survival, we measured the
density of interneurons labeled by immu-
nofluorescence staining for parvalbumin
or calretinin in NCAM-EC and WT cor-
tex. The density of parvalbumin cells
was equivalent to WT in the NCAM-EC cingulate cortex (supple-
mental Fig. S2, available at www.jneurosci.org as supplemental
material) as well as in the frontal association cortex, reticulotha-
lamic nucleus, and striatum (data not shown). The density of
calretinin cells was also unchanged in cingulate cortex (supple-
mental Fig. S2, available at www.jneurosci.org as supplemental
material) or frontal association cortex of transgenic mice (data
not shown). Furthermore, the density of basket interneurons in
the cingulate cortex of EGFP-NCAM mice was equivalent to that
in EGFP-WT mice. These results indicated that there was no loss
of neurons expressing parvalbumin or calretinin nor was there
loss of EGFP-expressing basket cell subpopulations in frontal
cortical areas of NCAM-EC transgenic mice.
Gross sensory and motor function appears normal in
NCAM-EC mice
Gross neurophysiological status was compared between WT and
NCAM-EC transgenic mice (supplemental Fig. S3, available at
www.jneurosci.org as supplemental material). Animals were
evaluated on appearance, orientation and reflexive behaviors,
postural and righting reflexes, paw strength, coordination, and
balance (Ribar et al., 2000). No differences were distinguished
among genotypes except in the latency to begin walking across a
vertical pole. Despite this fact, WT and mutant mice responded
similarly on the neurophysiological screen and did not appear to
posses any gross features that might compromise subsequent be-
havioral testing. Importantly, in the zero maze, WT and
NCAM-EC mice spent similar amounts of time in the open arms
(Fig. S3, available at www.jneurosci.org as supplemental mate-
rial). Hence, these findings suggest that the transgenic mice do
not present an anxiety-like phenotype (Shepherd et al., 1994).
NCAM-EC mice show increased basal activity and enhanced
amphetamine and MK-801 responses
Increased locomotor activity is often used as an index for
schizophrenia-like behavior in rodents (Lipska and Weinberger,
2000). Accordingly, spontaneous activity of WT and NCAM-EC
mice was measured in the open field over 1 h (Fig. 5A–C). Hori-
Figure 2. Immunofluorescence localization of GABAergic neuronal markers is decreased in synaptic puncta within the
NCAM-EC cerebral cortex. Immunofluorescent staining for GAD65, GAD67, or GAT-1 was analyzed in the cingulate and frontal
association cortex (layers II/III) of adult WT and NCAM-EC transgenic mice. Fluorescent puncta rings surrounding nonlabeled soma
are shown in confocal images by arrows; punctate staining in the neuropil is shown by arrowheads. Control staining with nonim-
mune IgG is shown in the insets. Quantification of immunofluorescence in puncta rings and neuropil by mean pixel density from
multiple images is depicted in bar graphs. *p  0.05 from the WT control. Scale bar, 10 m.
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zontal or locomotor activity was significantly higher for trans-
genic mice than for WT littermates (t(1,14)  2.310; p  0.037).
However, vertical or rearing activity was not distinguished by
genotype. In contrast, stereotypy or repetitive beam breaks (Fig.
5C) were found to be significantly increased in NCAM-EC mice
compared with WT controls (t(1,14)  2.306; p  0.037). These
data show that NCAM-EC mice display a significant increase in
spontaneous locomotor and stereotypical activities compared
with WT animals.
Because schizophrenic patients show enhanced sensitivity to
psychostimulants (Lieberman et al., 1987) and these drugs can
exacerbate psychotic symptoms (Janowsky et al., 1973), we eval-
uated the responses of WT and NCAM-EC mice to amphetamine
in the open field (Fig. 5D–F). Animals were placed into the open
field for 60 min to acclimate them to the apparatus and then were
injected with water or 2 or 4 mg/kg amphetamine and immedi-
ately returned to the open field for an additional hour. A univar-
iate ANOVA for locomotor activity demonstrated significant ef-
fects of genotype (F(1, 44)  12.627; p  0.001) and drug (F(2,44) 
43.297; p  0.001) as well as a significant genotype by drug inter-
action (F(2,44)  3.093; p  0.05). Bonferroni corrected pairwise
comparisons revealed that locomotion in NCAM-EC mice was
stimulated by both doses of amphetamine ( p  0.006) compared
with the vehicle control, whereas WT animals were responsive
only to the highest dose ( p  0.015). Moreover, 4 mg/kg amphet-
amine stimulated higher levels of locomotion in transgenic mice
than in WT littermates (Fig. 5D). For rearing, significant drug
effects were noted (F(2,44)  6.694; p  0.003) in which 2 and 4
mg/kg amphetamine suppressed activity ( p  0.015) but only in
WT mice (Fig. 5E). With respect to stereotypy, significant geno-
type (F(1,44)  12.698; p  0.001) and drug effects were obtained
(F(2,44)  44.953; p  0.001). Decomposition analyses revealed
that stereotypy in NCAM-EC mice was responsive to both doses
of amphetamine ( p  0.001), whereas WT animals were only
Figure 3. Fluorescent synaptic puncta of basket interneurons are decreased in the NCAM-EC cerebral cortex and amygdala. A, Fluorescent synaptic puncta of GABAergic basket interneurons are
decreased in the cingulate cortex (layers II/III) and amygdala (basolateral nucleus), but not the hippocampus (CA2 pyramidal cell layer shown), of adult NCAM-EC transgenic mice expressing EGFP
specifically in basket cells. Arrows point to puncta rings. Scale bar, 10 m. B, Quantification of fluorescence in puncta rings, expressed as mean pixel density, in WT and NCAM-EC cingulate cortex
(layers II/III), amygdala, and hippocampus (CA2 pyramidal cell layer). *p  0.05, from the WT mice. C, Colocalization of NCAM immunostaining with rhodamine-conjugated secondary antibodies
(red) with EGFP-expressing basket interneurons (green) in adult WT cingulate cortex and amygdala. Arrows indicate colocalization of NCAM immunoreactivity in synaptic puncta surrounding cell
bodies. D, Immunostaining for parvalbumin in cingulate cortex of EGFP-WT and EGFP-NCAM transgenic mice. Arrows show puncta rings. Insets, Control staining with nonimmune IgG. The graph
shows quantification of immunofluorescence of parvalbumin puncta rings in EGFP-WT and EGFP-NCAM cingulate cortex (layers II/III).
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activated by the highest dose ( p  0.001) (Fig. 5F). Hence, these
data show that locomotion and stereotypy in NCAM-EC mice are
more responsive to amphetamine than in the WT littermates.
Another model of schizophrenia-like behaviors in rodents in-
volves the use of NMDA receptor antagonists. In fact, phencycli-
dine elicits a wide range of psychotomimetic effects in humans
(Luby et al., 1962), and MK-801 or dizocilpine mimics some of
the features of schizophrenia in humans (Carlsson et al., 2001).
To determine whether the NCAM-EC mice may be more respon-
sive to MK-801 than WT controls, animals were tested with the
same protocol as that described for amphetamine above. When
the effects of MK-801 were examined on locomotor activity (Fig.
5G), significant genotype (F(1,65)  6.536; p  0.013), drug
(F(3,65)  31.239; p  0.001), and a genotype by drug interaction
were obtained (F(3,65)  2.928; p  0.048). Bonferroni-corrected
pairwise comparisons revealed that activity of WT and
NCAM-EC mice was significantly stimulated ( p  0.003) by 0.3
and 0.4 mg/kg MK-801 compared with the respective vehicle
controls. The pairwise analyses also showed that although no
significant differences in response between the 0.3 and 0.4 mg/kg
doses for WT mice, locomotion in transgenic animals was stim-
ulated to a greater extent by 0.4 mg/kg MK-801 ( p  0.001).
Moreover, NCAM-EC animals were more responsive to the high-
est dose of MK-801 ( p  0.003) than the WT controls (Fig. 5G).
Rearing was suppressed to equal extents in both genotypes by all
doses of MK-801 (F(3,65)  14.039; p  0.001) (Fig. 5H). Stereo-
typy to MK-801 mimicked virtually the same effects as that de-
scribed for locomotion above (genotype: F(1,65)  6.290; p 
0.015; drug: F(3,65)  37.750; p  0.001; genotype by drug inter-
action: F(3,65)  2.796; p  0.056). Decomposition analyses dem-
onstrated that all three doses of MK-801 were effective in stimu-
lating activity in both WT and transgenic mice ( p  0.05). Once
again, the 0.3 and 0.4 mg/kg comparison was only significant for
NCAM-EC animals ( p  0.016), and the WT and transgenic
animals only differed from each other ( p  0.001) at the 0.4
mg/kg dose (Fig. 5I). Thus, NCAM-EC transgenic mice are more
sensitive to the activity-stimulating effects of amphetamine and
MK-801 than WT littermates, suggesting that overexpression and
secretion of NCAM-EC may influence dopaminergic and glu-
taminergic neurotransmission and, therefore, be relevant to
schizophrenia and other psychiatric disorders associated with
dysfunction of these systems.
NCAM-EC transgenic mice are impaired in sensory gating
NCAM-EC transgenic mice were tested for sensory gating deficits
in PPI. Before testing, amplitudes of the startle response to the
120 dB stimulus were found to be equivalent in WT and
NCAM-EC mice (Fig. 6A, inset). When RMANOVA was applied
to the PPI results, significant prepulse intensity effects (F(2,38) 
12.763; p  0.001) and a genotype by prepulse intensity interac-
tion (F(2,38)  3.164; p  0.054) were noted. Decomposition
analyses demonstrated that transgenic mice displayed signifi-
cantly lower inhibition of the startle response ( p  0.006) than
WT controls at each of three prepulse intensities (Fig. 6A). Ex-
amination of the interaction revealed that WT mice could distin-
guish among each prepulse intensity ( p  0.022), whereas the
NCAM-EC mice did not appear capable of differentiating among
the stimuli. These data show that transgenic mice are deficient
both in the magnitude of inhibition of PPI responses and in
gating among the acoustic prepulse stimuli.
To determine whether sensory gating by the transgenic mice
was improved by treatment with antipsychotics, startle and PPI
responses were evaluated for mice given haloperidol or clozapine.
Before PPI testing, the amplitudes of the startle responses to the
120 dB startle stimulus were compared between WT and
NCAM-EC transgenic mice given vehicle or each of the drugs
(Fig. 6B). For WT and NCAM-EC mice, significant treatment
effects for startle responses were obtained for both haloperidol
(WT: F(1,32)  10.617; p  0.001; NCAM-EC: F(1,29)  27.260;
p  0.001) and clozapine (WT: F(1,32)  3.42; p  0.045; NCAM-
EC: F(1,23)  10.487; p  0.001). In all cases, 0.05 and 0.2 mg/kg
haloperidol and 1 and 3 mg/kg clozapine enhanced the magni-
tude of the startle response to the 120 dB stimulus over that of the
respective vehicle controls (WT, p  0.045; NCAM-EC, p 
0.003).
Effects of haloperidol and clozapine were evaluated separately
within each genotype. RMANOVA for WT mice given haloperi-
dol identified a significant main effect of prepulse intensity
(F(2,72)  74.510; p  0.001) and a significant prepulse by treat-
ment interaction (F(4,72)  14.001; p  0.001) (Fig. 6C,D). PPI
responses at 4 and 8 dB were lower for the vehicle controls and
animals given 0.05 mg/kg haloperidol ( p  0.007) than for WT
animals given 0.2 mg/kg haloperidol (Fig. 6C). When responses
Figure 4. Synaptophysin immunofluorescence and dendrite spine density are decreased in
NCAM-EC cingulate cortex. A, Immunofluorescent staining for synaptophysin was analyzed in
cingulate cortex (layers II/III) of adult WT and NCAM-EC transgenic mice. Fluorescent puncta
rings surrounding nonlabeled soma are shown in confocal images by arrows. Control staining
with nonimmune IgG is shown in the inset. B, Spines on apical dendritic branches in the cingu-
late cortex (layers II/III) of adult WT (Thy1/YFP line H) and transgenic mice (NCAM-EC/Thy1)
were calculated. Arrows indicate some of the spines on the dendrite. *p  0.05, from the WT
control. Scale bar, 10 m.
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under each drug condition were analyzed, it was found that mice
given vehicle or 0.05 mg/kg haloperidol could still sensory gate
( p  0.014), whereas those administered the higher dose of hal-
operidol could not differentiate among the prepulses. Hence, PPI
is enhanced by haloperidol; however, 0.2 mg/kg, but not the 0.05
mg/kg, dose disrupts sensory gating in the WT mice. In compar-
ison, in NCAM-EC animals, haloperidol did not alter PPI perfor-
mance over that of the vehicle control (Fig. 6D). Thus, transgenic
mice did not respond significantly to haloperidol.
In addition to evaluating effects of haloperidol on PPI, we also
studied responses to clozapine (Fig. 6E,F). RMANOVA of
WT responses revealed a significant effect of prepulse intensity
(F(2,64)  35.655; p  0.001) (Fig. 6E). These data show that WT
mice could still differentiate among the prepulses regardless of
vehicle– drug assignment. An examination of NCAM-EC re-
sponses gave a significant main effect of prepulse intensity
(F(2,46)  16.373; p  0.001) and a significant prepulse by treat-
ment interaction (F(4,46)  2.656; p  0.045). Decomposition
analyses demonstrated that NCAM-EC animals given 1 mg/kg
clozapine had higher PPI responses at 4 dB than the vehicle con-
trols ( p  0.001) and the animals given 3 mg/kg clozapine (Fig.
6F). Responses of the vehicle controls were also lower ( p 
0.001) than those given either dose of clozapine at prepulse in-
tensities of 8 or 12 dB. Additional comparisons confirmed that
NCAM-EC mice could not differentiate among the different pre-
pulses, whereas animals given 1 or 3 mg/kg clozapine successfully
gated the stimuli. Collectively, these findings showed that the
atypical antipsychotic clozapine, but not haloperidol, could nor-
malize PPI in NCAM-EC mice.
Impaired fear conditioning in NCAM-
EC transgenic mice
To test the associative learning capability
of NCAM-EC transgenic mice, animals
were tested for cued- and contextual-
dependent fear conditioning. Parentheti-
cally, cued fear conditioning is disrupted
by lesions of the amygdala but not the hip-
pocampus (Phillips and LeDoux, 1992;
Kim and Davis, 1993), whereas contextual
fear conditioning is mediated by the hip-
pocampus, amygdala, and periaqueductal
gray in addition to cingulate and frontal
cortex (Fendt and Fanselow, 1999). Dur-
ing conditioning, freezing behaviors were
not statistically different between the two
genotypes over the first 2 min of training,
during presentation of the tone shock, or
after the footshock (Fig. 7A). As might be
anticipated, however, an RMANOVA
found significant main effects of test pe-
riod (F(2,30)  59.188; p  0.001).
Bonferroni-corrected pairwise compari-
sons showed that this effect was a result of
a progressive increase in freezing behavior
from acclimatization to tone shock and
from tone shock to the postshock periods
for both genotypes of mice. In compari-
son, freezing behaviors were less pro-
nounced in transgenic mice than in WT
controls during contextual fear condition-
ing (F(4,60)  2.556; p  0.048) (Fig. 7B).
In fact, NCAM-EC transgenic mice dis-
played significantly lower levels of freezing
behavior in the contextual test than the WT littermates at all
times examined ( p  0.011). In the cued test, significant time
(F(4,60)  48.519; p  0.001) and a genotype by time interaction
were found (F(4,60)  17.383; p  0.001). Freezing responses were
low and were not distinguished by genotype before presentation
of the tone (Fig. 7C). However, when the tone was sounded,
freezing behavior immediately increased for WT animals while it
remained low for the NCAM-EC transgenic mice throughout
testing ( p  0.001). Despite this fact, there was some increment
in freezing behavior within the final block of testing for trans-
genic mice (minutes 1 and 2 vs 5; p  0.01). These findings
suggest that emotional learning and memory were impaired in
NCAM-EC transgenic mice.
Discussion
Here, we describe a novel transgenic mouse strain (NCAM-EC)
that expresses a soluble fragment of NCAM consisting of its ex-
tracellular domain in the brain. NCAM-EC transgenic mice dis-
played impaired synaptic connectivity involving GABAergic in-
terneurons evident by a decrease in perisomatic synaptic puncta
in the cingulate and frontal association cortex as well as the amyg-
dala. Defective sensory gating, impaired emotional memory, and
increased locomotor activities in NCAM-EC transgenic mice
may be a result of defective circuitry in these regions. The results
suggest that elevated shedding of the NCAM extracellular region
may perturb NCAM180-dependent neuronal recognition affect-
ing development or maintenance of inhibitory synapses in the
cerebral cortex and amygdala.
The similarities in behavioral phenotypes of NCAM-EC mice
Figure 5. NCAM-EC mice show enhanced basal activity and locomotion to amphetamine and MK-801. A–C, Mice were placed
in the open field, and spontaneous horizontal (A), vertical (B), and stereotypical (C) activities were monitored at 5 min intervals
over 1 h (n  7–9 mice/genotype; *p  0.05 from WT controls). D–F, Locomotor, rearing, and stereotypy of mice injected with
vehicle or 2 or 4 mg/kg, i.p. amphetamine (AMPH) are displayed. G–I, Locomotion, rearing, and stereotypy of mice given vehicle
or 0.2, 0.3, or 0.4 mg/kg, i.p. MK-801 [n  7–10 mice/genotype; #p  0.01; p  0.005 from the WT controls given the same
dose of AMPH/MK-801 as the NCAM-EC transgenic (Tg) mice].
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and NCAM null mutants suggest that the neurological defects of
the transgenic mice result from inhibition of NCAM function.
Both strains exhibit impaired PPI performance, deficiencies in
contextual and cued fear conditioning, and hyperlocomotion
(Wood et al., 1998; Stork et al., 2000). Behavioral deficits in
NCAM-EC mice probably arise from perturbation of NCAM180
function rather than NCAM140, because defective PPI (Wood et
al., 1998) and fear conditioning (Stork et al., 2000) result from loss of
NCAM180 specifically. Moreover, the olfactory bulb of NCAM-EC
transgenic mice was normal in size, whereas that of NCAM140
mice is small because of impaired migration of granule neurons
(Stork et al., 2000). Perturbation of NCAM180 function in
NCAM-EC mice is likely to occur at the postnatal stage, when en-
dogenous NCAM180 is upregulated and the NSE promoter is max-
imally activated (Forss-Petter et al., 1990).
Decreased numbers of presynaptic terminals of GABAergic
neurons in the frontal cortex and amygdala of NCAM-EC mice
were indicated by the reduction in perisomatic puncta rings im-
munoreactive for four different markers (GAD65, GAD67,
GAT-1, and parvalbumin) and in EGFP-labeled basket cells.
There is no loss of major interneuron subpopulations in the cin-
gulate cortex of transgenic mice, as shown for parvalbumin
interneurons, which account for 40 –50% of GABAergic inter-
neurons in the rodent neocortex (Kubota et al., 1994), for calreti-
nin interneurons, which account for 12% of GABAergic inter-
neurons in the mouse parietal cortex (Powell et al., 2003), or for
the EGFP basket cell subpopulation. These results suggested
that elevated expression of the soluble NCAM fragment perturbs
the development or maintenance of presynaptic axon terminals
of GABA interneurons. This finding is consistent with the known
function of NCAM in regulating synapse number (Schuster et al.,
1998; Dityatev et al., 2000), LTP (Luthl et al., 1994), and synaptic
maturation (Landmesser et al., 1988). By disturbing neuronal
connectivity, it is also possible that NCAM-EC might depress the
expression of these markers. For example, activity-dependent
regulation of GAD67 has been reported in interneurons (Hendry
and Jones, 1988; Benson et al., 1994). This effect might be medi-
ated by excitatory input from pyramidal cells (Melchitzky and
Lewis, 2003), although activity-dependent regulation of GAD65
and GAT-1 has been noted less consistently (Patz et al., 2003).
Figure 6. Prepulse inhibition of acoustic startle is decreased in NCAM-EC transgenic mice
and is restored with clozapine. A, Percentage of PPI responses of WT and NCAM-EC transgenic
(Tg) mice. Inset, Startle response to the 120 dB tone. *p  0.05, from the WT control. B, Startle
responses of WT and Tg mice administered vehicle, haloperidol, or clozapine (intraperitoneally).
*p  0.05, from the respective vehicle control within genotype. C, D, PPI of WT and Tg mice
given vehicle or 0.05 or 0.2 mg/kg haloperidol (intraperitoneally) ( #p  0.05, vehicle and 0.05
mg/kg haloperidol vs 0.2 mg/kg heloperidol). E, F, PPI of WT mice and Tg mice administered
vehicle or 1 or 3 mg/kg, i.p. clozapine (n  8 –12 mice/genotype/drug/dose; *p  0.05,
vehicle vs 1 mg/kg clozapine; p  0.05, vehicle vs 3 mg/kg clozapine; @p  0.05, 1 mg/kg vs
3 mg/kg clozapine).
Figure 7. Fear conditioning is decreased in NCAM-EC transgenic mice. A, Freezing behavior
of WT and NCAM-EC transgenic (Tg) mice during the first 2 min of conditioning, during the 30 s
tone-shock interval, and 30 s after tone shock. B, Percentage of freezing responses of WT and Tg
mice during each minute of the 5 min context test. C, Freezing behavior of WT and Tg mice
before and during tone presentation (cue) over the 5 min test. n  8 –9 mice/genotype; *p 
0.05 from the transgenic mice.
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The finding that synaptophysin-labeled puncta were also de-
creased in the neuropil as well as perisomatic sites in the cerebral
cortex of NCAM-EC transgenic mice suggested that connectivity
of classes of neurons other than GABAergic interneurons may be
perturbed, and that effects on interneurons could be indirect
results of defects in glutamatergic or dopaminergic neurotrans-
mission. Indeed, along with striking reductions in inhibitory syn-
apses, a decrease in synaptophysin immunoreactivity and pyra-
midal cell dendrite spine density in the cingulate cortex of
NCAM-EC mice suggests that there are decreases in excitatory
synapses. Furthermore, synapses within other brain regions and
cortical areas may be perturbed, because both the NCAM-EC
transgene and endogenous NCAM are widely expressed in the
brain.
Schizophrenia-related alteration in expression of genes in-
volved in GABA neurotransmission has been repeatedly docu-
mented in the prefrontal cortex of human patients (Blum and
Mann, 2002). Decreased expression of GAD67 (Akbarian et al.,
1995; Volk et al., 2000) and GAT-1 (Pierri et al., 1999; Volk et al.,
2001) in subpopulations of interneurons is observed consistently
(Woo et al., 1998; Lewis et al., 2001), along with changes in
GABAA receptors (Benes et al., 1996; Volk et al., 2002). Distur-
bances in chandelier axon terminals (Lewis et al., 2001) and bas-
ket interneurons have been implicated in working memory defi-
cits in schizophrenia (Hashimoto et al., 2003). GABAergic
dysfunction in the prefrontal cortex may perturb various cogni-
tive functions, because interneurons are involved in information
processing (Constantinidis et al., 2002). Although there was a
reduction in GABAergic synaptic puncta in frontal cortex and
amygdala of NCAM-EC mice, there was no reduction in
GAD65-, GAD67-, or EGFP-labeled puncta in the hippocampus.
Similarly, little or no reduction in GAD65 and GAD67 expression
is evident in the hippocampus in schizophrenia (Todtenkopf and
Benes, 1998; Heckers et al., 2002). Interestingly, a recent meta-
analysis of 20 genome scans for schizophrenia susceptibility
showed human chromosome region 11q22.3-q24.1, which en-
compasses the NCAM gene at 11q23.1, as the fourth-ranked can-
didate locus (Lewis et al., 2003).
Schizophrenia has been postulated to represent abnormalities
in dopaminergic and/or glutaminergic neurotransmission
(Carlsson et al., 2001). To assess responses of these systems, spon-
taneous activity was monitored in the open field. Under basal
conditions, locomotor and stereotypical activities are higher in
the NCAM-EC mice than in the WT controls. It is noteworthy
that NCAM null mutants also show a similar increase in activity
(Stork et al., 1999). The enhancement in baseline activity suggests
that the NCAM-EC mice may possess alterations within the basal
ganglia-thalamocortical circuitry. Additional support for this
idea derives from observations with amphetamine and MK-801
treatments. In both cases, the NCAM-EC mice are more respon-
sive to the locomotor-stimulating effects of these drugs than the
WT controls. These findings suggest that neurons within the
basal ganglia–thalamocortical circuit of NCAM-EC transgenic
mice are more sensitive to the locomotor-stimulating effects of
these agents than WT controls. Because GABAergic interneurons
in frontal cortical regions and other brain areas can exert pro-
found effects on this circuit (Sesack et al., 1995; Karler et al.,
1998), deficits in GABAergic terminals may underlie the hyper-
activity phenotype of the NCAM-EC animals and their enhanced
responsivity to amphetamine and MK-801.
A decrease in GABAergic nerve terminals in frontal cortex and
amygdala of NCAM-EC mice may disrupt the inhibitory limb of
the PPI circuit and impair sensory gating. PPI of the acoustic
response is mediated by a startle circuit that involves the auditory
cortex, superior colliculus, and pons, which integrates with an
inhibitory circuit comprised of inputs to the nucleus accumbens
from the medial prefrontal cortex, amygdala, and hippocampus
(Swerdlow et al., 2001). GABAergic neurotransmission in the
forebrain is important in the response, because PPI is disrupted
after infusion of the GABA antagonist picrotoxin into these brain
regions (Fendt et al., 2000). Treatment of NCAM-EC transgenic
mice with the atypical antipsychotic drug clozapine, but not the
dopamine D2 receptor antagonist haloperidol, improved the
ability of NCAM-EC transgenic mice to gate the auditory stimu-
lus. Interestingly, deficits in PPI in GAD65 KO mice are also
reversed by clozapine (Heldt et al., 2004). Clozapine is a broad-
spectrum antipsychotic that has weak affinity for dopamine D1,
D2, D3, and D5 receptors and substantial affinities for dopamine
D4, serotonergic, -adrenergic, muscarinic, and histaminergic
receptors (Ashby and Wang, 1996). The inability of haloperidol
to rescue PPI suggests that dopaminergic receptor signaling may
be relatively normal in the forebrain of the NCAM-EC mice. In
contrast, normalization of PPI responses by clozapine indicates
that serotonergic neurotransmission, perhaps mediated through
2A receptors, may be abnormal. It is interesting that serotonin
turnover and release in frontal cortex are stimulated by NMDA
receptor antagonists such as MK-801 (Martin et al., 1998) and
that in the open field, NCAM-EC mice are more responsive to
this drug than WT animals. Because the raphe nucleus sends
projections to the frontal cortex that synapse on GABA interneu-
rons and pyramidal cells (Smiley and Goldman-Rakic, 1996),
alterations in GABA function in this brain region could disrupt
PPI performance in NCAM-EC mice and become normalized by
clozapine treatment
In addition to deficits in PPI, NCAM-EC mice are also defi-
cient in fear conditioning. It should be emphasized that the im-
pairment in fear conditioning was most likely a result of abnor-
malities in learning and memory rather than increased
locomotion, because activities of WT and NCAM-EC mice were
very similar during the training phase of fear conditioning, and
the mice did not show evidence of impulsive behavior in the
neurophysiological screen. Because the transgenic mice are im-
paired in both contextual and cued fear conditioning, the results
suggest that emotional memory in extrahippocampal regions or
the amygdala is disrupted in these mutants (Phillips and LeDoux,
1992; Kim and Davis, 1993). In accord with this possibility, syn-
aptic terminals of labeled GABAergic interneurons are dimin-
ished in the amygdala but not in the hippocampus of NCAM-EC
transgenic mice. Moreover, NCAM is expressed on synaptic
puncta of basket cells in the basolateral nucleus of the amygdala
(shown here) as well as on interneuron-like cells in almost all
amygdaloid nuclei in the rat (Nacher et al., 2002). In addition to
the amygdala, GABAergic dysfunction in frontal cortical regions
of NCAM-EC mice may also contribute to the deficits in fear
conditioning, because these areas are known to regulate amyg-
dala function in affective conditioning in rodents (Rosenkranz et
al., 2003). In this regard, it is interesting that GAD65 null mutant
mice are also deficient in fear conditioning (Stork et al., 2003).
Deficits in sensory gating, emotional memory, and locomotor
activities of NCAM-EC transgenic mice have been observed in
other rodent models of schizophrenia-like behavior, including
calcineurin conditional knockouts (Miyakawa et al., 2003), do-
pamine transporter mutants (Gainetdinov et al., 2001), NMDA
receptor hypomorphs (Mohn et al., 1999), and mice with ventral
hippocampal lesions (Lipska and Weinberger, 2000). However,
NCAM dysregulation has been linked with other diseases, includ-
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ing bipolar disorder (Vawter, 2000; Arai et al., 2004) and Alzhei-
mer’s dementia (Todaro et al., 2004). Thus, the NCAM-EC trans-
genic mouse line provides a new model for investigating a subset
of behavioral and neuropathogenic features that may provide
unique insights into basic mechanisms that underlie certain neu-
ropsychiatric disorders.
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